Avi Biopharma, Inc.

Company Information

Company Name
Avi Biopharma, Inc.
Address
Avi Biopharma, Inc.
4575 Sw Research Way, Ste 200
Corvallis, OR, 97333 0106
Phone
1 541-753-3635
URL
n/a
DUNS
n/a
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$920,111.00
5
STTR Phase I
$262,849.00
3
STTR Phase II
$424,266.00
1

Award List

  1. N/A

    Amount: $0.00

    N/A

    STTR Phase I 2000 Department of Health and Human Services
  2. N/A

    Amount: $424,266.00

    N/A

    STTR Phase II 2000 Department of Health and Human Services
  3. N/A

    Amount: $98,415.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  4. Inhibition of Androgen Receptor to treat Prostate Cancer

    Amount: $250,000.00

    DESCRIPTION (provided by applicant): Prostate cancer is the second leading cause of cancer death in US men. Prostate cancer is highly dependent on androgen stimulation mediated through the androgen ...

    SBIR Phase I 2003 Department of Health and Human Services
  5. Antisense Morpholino Oligomers to Treat Retinopathy

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The broad, long-term objectives of the application are to develop antisense inhibitors of retinopathy and document their mechanism(s) of action. Retinopathy is a s ...

    SBIR Phase I 2003 Department of Health and Human Services
  6. Morpholino Antisense Drugs for Hepatitis C Virus

    Amount: $164,078.00

    DESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) causes a persistent infection in most humans exposed to the virus. HCV infection in time can lead to cirrhosis and hepatocellular carcinom ...

    STTR Phase I 2004 Department of Health and Human Services
  7. Apoptotic Regulation of Lymphocyte Responses

    Amount: $107,000.00

    DESCRIPTION (provided by applicant): The response of lymphocytes to antigen stimulation is characterized by proliferation of an antigen-sensitive lymphocyte population, subsequent differentiation to s ...

    SBIR Phase I 2005 Department of Health and Human Services
  8. Antisense Antiviral Agent for West Nile Infections

    Amount: $364,696.00

    DESCRIPTION (provided by applicant): AVI BioPharma has been developing an antisense phosphorodiamidate morpholino oligomer, AVI-4020 for the treatment of West Nile Virus. AVI-4020 has been shown both ...

    SBIR Phase I 2005 Department of Health and Human Services
  9. THERAPEUTIC APPLICATIONS OF PERFLUOROCARBON MICROBUBBLES

    Amount: $98,771.00

    N/A

    STTR Phase I 1998 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government